← Back to Patent Explorer
US5350676A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for performing fibrinogen assays using dry chemical reagents containing magnetic particles

Assignee: Cardiovascular Diagnostics Inc
•
Filing: 1993-05-17
•
Granted: 1994-09-27
•
Expires: 2013-05-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An apparatus and a method for performing a fibrinogen assay are disclosed. The reaction slide bears a sample well for receiving a liquid sample and a reaction chamber in fluid communication with the sample well. The reaction chamber contains a dry reagent matrix in which is embedded a plurality of magnetic particles. A whole blood or blood-derived sample added to the sample well is introduced simultaneously into the reaction chamber where it solubilizes the reagent, freeing the magnetic particles and allowing them to move in an oscillating pattern. This oscillating pattern is optically monitored to measure the concentration of clottable fibrinogen in the sample.

Inventors

  • 👤 Bruce J. Oberhardt
  • 👤 Nancy Gresalfi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 18:59
CPC Classifications
B; B01; B01L; B01L3/00; B01L3/50; B01L3/502; G; G01; G01N; G01N33/00; G01N33/48; G01N33/483; G01N33/487; G01N33/49; G01N33/4905; G01N33/50; G01N33/86; G01N35/00; G01N35/0098; G01N2333/00; G01N2333/435; G01N2333/745; G01N2333/75

Claims Analysis

Total Claims: 25
Claim 1
Independent Claim 360 words
A method of performing a fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample and (2) a reaction chamber containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said reagent is a protease which acts directly on fibrinogen and induces fibrin polymerization; said sample well and reaction chamber being in fluid connection through a transport zone of geometry such that a volume of liquid analyte sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber; (ii) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or a blood-derived sample to said sample well whereby said sample is introduced into said reaction chamber, said reagent is solubilized and said particles are freed to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; (iii) optically monitoring said reaction chamber to measure one or more of the following parameters (iiia) said start time and said stop time for said fibrinogen assay, or (iiib) the maximum amplitude of said particle oscillation, A, and the subsequent residual, post peak minimum amplitude, B, of said particle oscillation, or (iiic) the slope of said particle oscillation curve or area defined by said curve in the region between A and B; and (iv) using said start time and said stop time, or at least B, or said slope, or said area to correlate at least one of said parameters (iiia)-(iiic) to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 2
Independent Claim 360 words
A method of performing a fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample and (2) a reaction chamber containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said reagent is a protease which acts directly on fibrinogen and induces fibrin polymerization; said sample well and reaction chamber being in fluid connection through a transport zone of geometry such that a volume of liquid analyte sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber; (ii) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or a blood-derived sample to said sample well whereby said sample is introduced into said reaction chamber, said reagent is solubilized and said particles are freed to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; (iii) optically monitoring said reaction chamber to measure one or more of the following parameters (iiia) said start time and said stop time for said fibrinogen assay, or (iiib) the maximum amplitude of said particle oscillation, A, and the subsequent residual, post peak minimum amplitude, B, of said particle oscillation, or (iiic) the slope of said particle oscillation curve or area defined by said curve in the region between A and B; and (iv) using said start time and said stop time, or at least B, or said slope, or said area to correlate at least one of said parameters (iiia)-(iiic) to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 3
Dependent Claim 32 words
The method of claim 1, wherein said protease is one member selected from the group consisting of human thrombin, bovine thrombin, reptilase, copper head venom enzyme, or Malayan pit viper venom enzyme
Claim 4
Independent Claim 298 words
A method of performing a clottable fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample and (2) a reaction chamber containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said reagent is a fibrinogen assay reagent which acts directly on fibrinogen to induce fibrin polymerization; said sample well and reaction chamber being in fluid connection through a transport zone of geometry such that a volume of liquid analyte sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber; (ii) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or a blood-derived sample to said sample well whereby said sample is introduced into said reaction chamber, said reagent is solubilized and said particles are freed to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; (iii) optically monitoring said reaction chamber to measure said start time and said stop time for said fibrinogen assay; and (iv) using said start time and said stop time to correlate said start and stop time to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 5
Independent Claim 298 words
A method of performing a clottable fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample and (2) a reaction chamber containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said reagent is a fibrinogen assay reagent which acts directly on fibrinogen to induce fibrin polymerization; said sample well and reaction chamber being in fluid connection through a transport zone of geometry such that a volume of liquid analyte sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber; (ii) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or a blood-derived sample to said sample well whereby said sample is introduced into said reaction chamber, said reagent is solubilized and said particles are freed to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; (iii) optically monitoring said reaction chamber to measure said start time and said stop time for said fibrinogen assay; and (iv) using said start time and said stop time to correlate said start and stop time to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 6
Dependent Claim 11 words
The method of claim 3, wherein said dry reagent comprises thrombin.
Claim 7
Dependent Claim 20 words
The method of claim 3, wherein said dry reagent comprises reptilase, copperhead venom enzyme, or Malayan pit viper venom enzyme.
Claim 8
Independent Claim 333 words
A method of performing a fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample, (2) a reaction chamber, and (3) a conduit means situated between said sample well and said reaction chamber and being in fluid communication therewith; said reaction chamber containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said dry reagent matrix is present only in said reaction chamber, and wherein said reagent is a fibrinogen assay reagent which acts directly on fibrinogen to induce fibrin polymerization; (ii) under conditions suitable for conducting a fibrinogen assay, adding a volume of a whole blood or a blood-derived sample to said sample well, said volume of said sample being sufficient to substantially fill said conduit means without entering said reaction chamber or contacting said dry reagent matrix; (iii) adding a volume of buffer diluent to said sample well, said volume of said buffer being sufficient to wash said sample into said reaction chamber thereby causing said reagent to become solubilized and freeing the particles to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; (iv) optically monitoring the oscillation of said magnetic particles to measure said start time and said stop time for the fibrinogen assay; and (v) using the start time and the stop time to correlate said start and stop time to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 9
Independent Claim 333 words
A method of performing a fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample, (2) a reaction chamber, and (3) a conduit means situated between said sample well and said reaction chamber and being in fluid communication therewith; said reaction chamber containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said dry reagent matrix is present only in said reaction chamber, and wherein said reagent is a fibrinogen assay reagent which acts directly on fibrinogen to induce fibrin polymerization; (ii) under conditions suitable for conducting a fibrinogen assay, adding a volume of a whole blood or a blood-derived sample to said sample well, said volume of said sample being sufficient to substantially fill said conduit means without entering said reaction chamber or contacting said dry reagent matrix; (iii) adding a volume of buffer diluent to said sample well, said volume of said buffer being sufficient to wash said sample into said reaction chamber thereby causing said reagent to become solubilized and freeing the particles to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; (iv) optically monitoring the oscillation of said magnetic particles to measure said start time and said stop time for the fibrinogen assay; and (v) using the start time and the stop time to correlate said start and stop time to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 10
Independent Claim 305 words
A method of performing a clottable fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample and (2) a reaction chamber containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said reagent is a fibrinogen assay reagent which act directly on fibrinogen to induce fibrin polymerization; said sample well and reaction chamber being in fluid connection through a transport zone of geometry such that a volume of liquid analyte sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber; (ii) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or a blood-derived sample to said sample well whereby said sample is introduced into said reaction chamber, said reagent is solubilized and said particles are freed to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under and area above the oscillation curve; (iii) optically monitoring said reaction chamber to measure the maximum amplitude of said particle oscillation, A, and the subsequent residual, post peak minimum amplitude, B, of said particle oscillation; and (iv) using at least B to correlate at least B to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 11
Independent Claim 305 words
A method of performing a clottable fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample and (2) a reaction chamber containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said reagent is a fibrinogen assay reagent which act directly on fibrinogen to induce fibrin polymerization; said sample well and reaction chamber being in fluid connection through a transport zone of geometry such that a volume of liquid analyte sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber; (ii) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or a blood-derived sample to said sample well whereby said sample is introduced into said reaction chamber, said reagent is solubilized and said particles are freed to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under and area above the oscillation curve; (iii) optically monitoring said reaction chamber to measure the maximum amplitude of said particle oscillation, A, and the subsequent residual, post peak minimum amplitude, B, of said particle oscillation; and (iv) using at least B to correlate at least B to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 12
Dependent Claim 18 words
The method of claim 7, wherein only B is used to measure said fibrinogen concentration in said sample.
Claim 13
Dependent Claim 21 words
The method of claim 7, wherein a ratio A/B or B/A is used to measure said fibrinogen concentration in said sample.
Claim 14
Dependent Claim 17 words
The method of claim 7, wherein A-B is used to measure said fibrinogen concentration in said sample.
Claim 15
Dependent Claim 19 words
The method of claim 7, wherein (A-B)÷A or A÷(A-B) is used to measure said fibrinogen concentration in said sample.
Claim 16
Dependent Claim 19 words
The method of claim 7, wherein A/B and (A-B)÷A are used to measure said fibrinogen concentration of said sample.
Claim 17
Dependent Claim 29 words
The method of claim 7, wherein the slope of the oscillation curve taken at a region between A and B is used to determined fibrinogen concentration of said sample.
Claim 18
Dependent Claim 37 words
The method of claim 7, wherein the area either above or below the oscillation curve as defined by the region between A and B or a portion thereof is used to determine fibrinogen concentration of said sample.
Claim 19
Dependent Claim 11 words
The method of claim 7, wherein said dry reagent comprises thrombin.
Claim 20
Dependent Claim 20 words
The method of claim 7, wherein said dry reagent comprises reptilase, copperhead venom enzyme, or Malayan pit viper venom enzyme.
Claim 21
Independent Claim 363 words
A method of performing a fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample, (2) a reaction chamber, and (3) a conduit means situated between said sample well and said reaction chamber and being in fluid communication therewith; said conduit means containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said dry reagent is present only in said conduit, and wherein said reagent is a fibrinogen assay reagent which acts directly on fibrinogen to induce fibrin polymerization; (ii) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or blood-derived sample to said sample well, the volume of said sample being sufficient to substantially fill said conduit means and reaction chamber and to mix with said reagent and wash said reagent into said reaction chamber thereby freeing said magnetic particles to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a Stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; (iii) optically monitoring said reaction chamber to measure one or more of the following parameters (iiia) said start time and said stop time for said fibrinogen assay, or (iiib) the maximum amplitude of said particle oscillation, A, and the subsequent residual, post peak minimum amplitude, B, of said particle oscillation, or (iiic) the slope of said particle oscillation curve or area defined by said curve in the region between A and B; and (iv) using said start time and said stop time, or at least B, or said slope, or said area to correlate at least one of said parameters (iiia)-(iiic) to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen is said whole blood or blood-derived samples.
Claim 22
Independent Claim 363 words
A method of performing a fibrinogen assay, comprising: (i) subjecting to an oscillating magnetic field a reaction slide bearing (1) a sample well for receiving a liquid sample, (2) a reaction chamber, and (3) a conduit means situated between said sample well and said reaction chamber and being in fluid communication therewith; said conduit means containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said dry reagent is present only in said conduit, and wherein said reagent is a fibrinogen assay reagent which acts directly on fibrinogen to induce fibrin polymerization; (ii) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or blood-derived sample to said sample well, the volume of said sample being sufficient to substantially fill said conduit means and reaction chamber and to mix with said reagent and wash said reagent into said reaction chamber thereby freeing said magnetic particles to move in an oscillating pattern induced by said oscillating magnetic field, wherein said oscillating pattern has a start time and a Stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; (iii) optically monitoring said reaction chamber to measure one or more of the following parameters (iiia) said start time and said stop time for said fibrinogen assay, or (iiib) the maximum amplitude of said particle oscillation, A, and the subsequent residual, post peak minimum amplitude, B, of said particle oscillation, or (iiic) the slope of said particle oscillation curve or area defined by said curve in the region between A and B; and (iv) using said start time and said stop time, or at least B, or said slope, or said area to correlate at least one of said parameters (iiia)-(iiic) to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen is said whole blood or blood-derived samples.
Claim 23
Dependent Claim 52 words
The method of claim 7, wherein, before step (ii), a volume of distilled water is added to said sample well, sufficient to be taken into said conduit via capillary action thereby solubilizing said dry reagent and freeing said magnetic particles prior to the addition of said whole blood or said blood-derived sample.
Claim 24
Independent Claim 369 words
A method for performing a fibrinogen assay, comprising: (i) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or blood-derived sample to a sample well of a reaction slide, said reaction slide bearing (1) said sample well for receiving a liquid sample, (2) a reaction chamber, and (3) a conduit means situated between said sample well and said reaction chamber and being in fluid communication therewith; said conduit means containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said dry reagent matrix is present only in said conduit, and wherein said reagent is a fibrinogen assay reagent which acts directly on fibrinogen to induce fibrin polymerization; wherein the volume of said whole blood or said blood-derived sample added to said sample well is sufficient to substantially fill said conduit means and said reaction chamber and to wash said reagent into said reaction chamber thereby freeing said magnetic particles; (ii) subjecting said reaction slide to an oscillating magnetic field either at the time of addition of said whole blood or said blood-derived sample to said sample well or shortly thereafter, wherein said oscillating magnetic field causes said freed magnetic particles to move in an oscillating pattern, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; and (iii) optically monitoring said reaction chamber to measure one or more of the following parameters (iiia) at least the post peak minimum amplitude of said magnetic particle oscillation, (B), or (iiib) the slope of said particle oscillation curve, or (iiic) the area defined by the curve between the maximum amplitude of said particle oscillation, A, and B, to correlate at least one of said parameters (iiia)-(iiic) to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.
Claim 25
Independent Claim 369 words
A method for performing a fibrinogen assay, comprising: (i) under conditions suitable for conducting a fibrinogen assay, adding a whole blood or blood-derived sample to a sample well of a reaction slide, said reaction slide bearing (1) said sample well for receiving a liquid sample, (2) a reaction chamber, and (3) a conduit means situated between said sample well and said reaction chamber and being in fluid communication therewith; said conduit means containing a dry reagent matrix in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, wherein said dry reagent matrix is present only in said conduit, and wherein said reagent is a fibrinogen assay reagent which acts directly on fibrinogen to induce fibrin polymerization; wherein the volume of said whole blood or said blood-derived sample added to said sample well is sufficient to substantially fill said conduit means and said reaction chamber and to wash said reagent into said reaction chamber thereby freeing said magnetic particles; (ii) subjecting said reaction slide to an oscillating magnetic field either at the time of addition of said whole blood or said blood-derived sample to said sample well or shortly thereafter, wherein said oscillating magnetic field causes said freed magnetic particles to move in an oscillating pattern, wherein said oscillating pattern has a start time and a stop time, corresponding to a change in the degree of particle movement relative to said oscillating magnetic field, said oscillating pattern rises in a kinetic particle oscillation curve to a peak maximum amplitude of particle oscillation, decreases to a post peak minimum amplitude of particle oscillation, and said kinetic particle oscillation curve has a measurable slope and area under the oscillation curve; and (iii) optically monitoring said reaction chamber to measure one or more of the following parameters (iiia) at least the post peak minimum amplitude of said magnetic particle oscillation, (B), or (iiib) the slope of said particle oscillation curve, or (iiic) the area defined by the curve between the maximum amplitude of said particle oscillation, A, and B, to correlate at least one of said parameters (iiia)-(iiic) to the concentration of clottable fibrinogen in standard samples to measure the concentration of clottable fibrinogen in said whole blood or blood-derived sample.

References Cited (Backward Citations)

AU4798172A Cited
US3861197A Cited
US4756884A Cited
US4849340A Cited
US5110727A Cited
US5156974A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-09-26 1998-03-28 1998-09-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-09-26 2002-03-28 2002-09-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-09-26 2006-03-28 2006-09-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag